HSPB7 and cancer: Furthermore, HSPB7 relative promoter methylation was significantly increased in nine cancer types by 1.07‐ to 1.37‐fold and reduced only in lung squamous cell and thyroid cancers by 0.9‐ and 0.83‐fold, respectively (P < 0.005; Fig. 3B and Table S3).